The current study was aimed to investigate the metabolic changes associated with FASN inhibition in non-small cell lung cancer (NSCLC) cell lines with various molecular genetic abnormalities that affect FASN expression activity levels. Here, FASN is linked to non-small cell lung carcinoma.